Here are the S-3 shelf registrations from Vivos Therapeutics, Inc. (VVOS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow VVOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VVOS filings page.
Vivos Therapeutics, Inc. registers 3,964,712 shares of Common Stock issuable upon exercise of two private-placement warrants (1,982,356 shares under a five-year Series A Warrant and 1,982,356 shares under a 24-month Series B Warrant).
This prospectus covers resale by the selling stockholder and states the company will not receive proceeds from sales by the selling stockholder, although the company may receive proceeds if the Warrants are exercised for cash. The filing describes the warrants’ $2.09 exercise price, Nasdaq listing (VVOS), recent last sale price of $0.85 per share (April 28, 2026), and context on the company’s pivot to a medical-provider focused MSO/DSO model and its integration of The Sleep Center of Nevada.
Vivos Therapeutics, Inc. filed a resale registration covering 3,964,712 shares of common stock issuable upon exercise of two series of investor warrants. A five-year Series A warrant and a 24-month Series B warrant each allow purchase of up to 1,982,356 shares at an exercise price of $2.09 per share.
The company is not selling any shares in this offering and will not receive proceeds from selling stockholder resales, but may receive up to approximately $8.29 million if the warrants are exercised for cash. Vivos will bear registration costs, while the selling stockholder pays its own selling expenses. The registered shares may be sold from time to time on Nasdaq, where Vivos trades under the symbol VVOS.